Terray Therapeutics
PrivateLast Round
Series B
Oct 17, 2024
Est. Valuation
$600M
Total Funding Raised
$220M
Company Overview
Terray Therapeutics is a biotechnology company that delivers precise chemical datasets to enhance drug discovery through the integration of artificial intelligence, synthetic chemistry, automation, and nanotechnology.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Terray Therapeutics Comparables
Compare Terray Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genesis Therapeutics | 87% | |
| Iambic Therapeutics | 86% | |
| Recursion Pharmaceuticals | 84% |
Terray Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 17, 2024 | ||||
| Series A | Feb 15, 2022 | ||||
| Seed | Jun 30, 2021 |
Key People
Founding team and executive leadership
Terray Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Maverick Capital | Series B |
| Digitalis Ventures | Seed, Series A, Series B |
| Maverick Capital | Series B |
| Greentrail Partners | Series A |
| XTX Markets | Series A |
| Two Sigma Ventures | Series B, Series A, Seed |
| Alexandria Venture Investments | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 16, 2026
Monthly visitors grew 41% MoM, reaching 33.2K.
- Nov 17, 2025
Launched an experiment-driven ML platform for small-molecule discovery.
Terray Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Terray Therapeutics's valuation, stock price, and market status.
Is Terray Therapeutics a public or private company?
Terray Therapeutics is a private company.
What is the current stock price of Terray Therapeutics?
Terray Therapeutics is a private company, so its shares have no public market price. Caplight tracks Terray Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Terray Therapeutics worth (valuation)?
Terray Therapeutics's valuation is estimated at $600.0M based on funding round data.
Can I buy Terray Therapeutics stock?
Terray Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Terray Therapeutics's last funding round?
Terray Therapeutics's most recent funding round was Series B on October 17, 2024.
Who are the main investors in Terray Therapeutics?
Key investors in Terray Therapeutics include Digitalis Ventures, Two Sigma Ventures, NVentures, Madrona Venture Group, Bedford Ridge Capital.
Will Terray Therapeutics IPO soon?
No public IPO plans have been announced for Terray Therapeutics.
How can I track Terray Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Terray Therapeutics's shares on secondary markets.